- Daily Deal Round Up: May 20, 2022 •
- This is how Chinese VC differs from US… •
- GCV Symposium: Healthcare impact funds need to work… •
- GCV Symposium: Sustainability takes centre stage •
- Daily Deal Round Up: May 19, 2022 •
- Rising Stars Q&A – Galina Rachenkova, Hitachi Ventures •
- GCV Symposium fireside chat: Don’t panic over crypto… •
- Global Venturing Review: Amy Burr - JetBlue Technology… •
- Space Camp launches Mission 9 •
- GCV Symposium keynote interview: Sir Martin Sorell announces… •
- GCV Symposium keynote interview: “As investors, we need… •
- GCV Symposium panel: Government-based VC funding for security… •
Daily Deal Round Up: May 20, 2022
The Global Corporate Venturing deal net rounds up investments from across the corporate innovation ecosystem.
Daily Deal Round Up: May 6, 2022
The Global Corporate Venturing deal net rounds up the smaller investments from across the corporate innovation ecosystem.
HilleVax racks up $200m in its IPO
The Takeda Vaccines spinoff floated in an upsized offering that granted its former parent $100m in shares.
GemPharmatech gets $175m in initial public offering
The Sinopharm-backed laboratory animal model developer floated on Shanghai Stock Exchange’s Star Market two years after its last equity funding.
Hinova implements $166m IPO
Tigermed, Fosun, Haisco and Sinopharm-CICC all scored exits as the oncology and metabolic disorder therapeutics went public in China.
Microba makes tracks to ASX
The Macrogen-backed gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.
RecBio delivers IPO
The China Resources and Legend Holdings-backed vaccine technology developer floated in Hong Kong in a $97.7m offering following nearly $460m in funding.
AN2 Therapeutics prices $69m IPO
The Brii Biosciences-backed lung disease treatment developer priced an upsized offering in the middle of its range.
Daily Deal Round Up: February 28, 2022
Data analytics engineering group DBT Labs closed a $222m series D round including several corproates while 4Paradigm has filed an IPO prospectus again after its earlier attempt expired.
Circle doubles reverse merger valuation to $9bn
The blockchain payment platform developer’s valuation through its imminent reverse takeover has doubled, buoyed by the popularity of its stablecoin.
D-Wave agrees to $1.6bn reverse merger
The NEC-backed quantum computing system developer is set to list on the New York Stock Exchange through the transaction.
Daily Deal Round Up: February 8, 2022
SoftBank Vision Fund 2 led a $300m round for business-to-business marketplace ElasticRun and co-led blockchain creation platform developer Aleo's $200m series B.
Akili Interactive accedes to $1bn reverse merger
The Merck Group, Amgen, Shionogi, Kaiser Permanente and Digital Garage-backed digital cognitive treatment developer will get a Nasdaq Capital Market listing through the deal.
Braze breaches public markets in $520m IPO
Citi Ventures-backed Braze priced the offering above its range and it valued the customer engagement software producer at almost $5.9bn.
Paytm puts together $2.5bn IPO
The Alibaba, Ant Group, Berkshire Hathaway, Intel and SoftBank-backed e-commerce payment app operator is set to list on the NSE and BSE next week at a potential valuation of up to $18.7bn.
Rivian motors to $11.9bn IPO
Amazon, Ford, Cox Enterprises, Abdul Latif Jameel and Sumitomo are all notching up exits, as the electric jeep producer priced the largest initial public offering of 2021.